Fully human antibody development services

Are you seeking to develop a highly promising therapeutic antibody? In the race to develop groundbreaking therapeutic antibodies, fully human antibodies are your key to success. With over 50% of FDA-approved therapeutic antibodies now being fully human, choosing this approach significantly increases your chances of regulatory approval.
As a leading therapeutic antibody development company, ProteoGenix offers you unparalleled diversity in fully human antibody development technologies to accelerate your drug discovery process:

• Single B cell screening on humanized mice: This method ensures the identification of high-quality leads, with a guaranteed screening of 960 positive clones.
• Human phage display antibody libraries: Benefit from our exclusive proprietary libraries (3 naïve and 3 immune libraries from cancer, autoimmune diseases, and COVID-19 human donors).

 
By selecting ProteoGenix, you gain access to the most diverse range of fully human antibody development solutions, empowering you to bring innovative therapeutics to market faster. Let’s innovate together !

Why fully human antibodies are the preferred choice in biotherapeutics?

Therapeutic antibodies have revolutionized the treatment of numerous diseases. However, early versions, derived from mice, often encountered a significant challenge: the human anti-mouse antibody (HAMA) response. When injected into humans, these mouse-derived antibodies were recognized as foreign by the human immune system, leading to the production of human antibodies against the mouse antibodies. This HAMA response could neutralize the therapeutic antibody, reducing its efficacy and potentially causing adverse side effects.

To overcome the limitations of mouse-derived antibodies, researchers developed techniques to produce increasingly humanized antibodies. Today, fully human antibodies dominate the market. These molecules, generated directly from human genetic sequences, offer several key advantages:

• Elimination of the HAMA response: By being entirely human, these antibodies are not recognized as foreign by the human immune system, completely eliminating the risk of a HAMA response. This results in improved treatment tolerability and efficacy.
• Enhanced safety: Beyond the absence of HAMA, fully human antibodies generally exhibit a better safety profile with fewer adverse side effects.
• Optimal efficacy: Their high specificity and affinity for the therapeutic target ensure maximum efficacy, uncompromised by an immune response.
• Accelerated development: Modern production methods, such as phage display, enable the rapid generation of large panels of fully human antibodies, eliminating the time-consuming humanization steps required for mouse-derived antibodies.

 
In summary, fully human antibodies represent the future of biotherapeutics. By addressing the critical issue of the HAMA response and offering a superior safety and efficacy profile, they have become the gold standard in the development of new treatments.

Which fully human antibody discovery platform to choose for your project?

Selecting the right antibody development strategy is crucial for project success. At ProteoGenix, we offer multiple cutting-edge platforms, each tailored to meet specific project requirements. Here’s an overview of our most popular options:

Phage display with human libraries: rapid antibody discovery for cancer, autoimmune diseases, and COVID-19

Phage display technology stands out for its speed and versatility, delivering antibodies in just 4 weeks. This method excels with challenging antigens, whether toxic or non-immunogenic, consistently identifying binders in nearly all cases. Key advantages of our phage display platform:

• Ready-to-use naïve and immune libraries
• Ideal for toxic or non-immunogenic antigens
• Requires minimal antigen quantity (approximately 1mg)
• Access to our exclusive immune human libraries for cancer, autoimmune diseases, and COVID-19 targets

Single B cell screening: high-specificity antibodies in large numbers

Single B cell screening is the go-to solution for generating highly specific antibodies against your target antigen. This innovative technique leverages humanized mouse immunization, resulting in antibodies that have undergone in vivo affinity maturation. Key benefits of our single B cell screening platform:

• Produces highly specific and affine antibodies
• Ideal for generating a large number of antibodies
• Preserves natural pairing of heavy and light chains, enhancing developability
• Allows sorting of numerous B cells based on target antigen affinity

 
By offering both phage display and single B cell screening technologies, ProteoGenix ensures that you have access to the most suitable platform for your unique project needs. Our expert team is ready to guide you in selecting the optimal strategy, setting your antibody development project on the path to success from day one.

Success Story: development of human anti-TREM-2 antibodies for Alzheimer’s disease treatment

In collaboration with Isar Biosciences, ProteoGenix has developed groundbreaking human anti-TREM-2 antibodies. Targeting a key receptor involved in the brain’s immune response, these antibodies hold significant promise for Alzheimer’s disease treatment. Our approach has resulted in patented antibodies.
Learn more: https://us.proteogenix.science/scientific-corner/customers-success-stories/antibodies-for-alzheimers-disease/